IP2IPO invests in Scottish IP (intellectual property) commercialisation fund:
This article was originally published in Clinica
Executive Summary
IP2IPO, the London, UK-based intellectual property (IP) company that specialises in commercialising university technology, is extending its interest to Scotland. The AIM-listed firm has subscribed to a 5% stake in Edinburgh-based Sigma Technology Group, with which it will enter a collaboration to support the latter in its efforts to develop IP commercialisation efforts with Scottish universities. It has also take an option to subscribe to an additional 15% stake before June 30 2006.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.